SOURCE: Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc.

February 02, 2016 09:00 ET

Plandai Biotechnology, Inc. Announces New Product With Coyne Healthcare

Coyne Healthcare to Launch ph²™ Product at the End of March

LONDON, UNITED KINGDOM--(Marketwired - Feb 2, 2016) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced a license agreement with Coyne Healthcare for a new product which will utilize the Company's Pheroid® entrapped Phytofare® catechin complex -- trade named "ph²™"-- in a high-end consumer product for therapeutic and various other applications. Under the agreement, Plandaí will prepare the ph2 capsules for Coyne who will then bottle, package and sell the product, first in South Africa with an international launch targeted later this year.

ph2™ is the combination of the nano-entrapment system, Pheroid® with the Company's Phytofare® catechin complex. Pheroid® encapsulates, or entraps, the Phytofare® in a long-chain fatty-acid which both improves absorption and protects the Phytofare® against metabolization during the digestive process. Pheroid® is actively used worldwide for industrial and agricultural purposes and has been extensively tested in humans and animals where it has shown an ability to significantly increase the level of absorption of the entrapped particles into the bloodstream. The new Coyne Healthcare product represents the first application of Phytofare® and Pheroid® (branded "ph²™") in a commercial product intended for human use.

Callum Cottrell-Duffield, Vice President of Plandaí, commented, "Coyne Healthcare's vision for creating a high-end wellness product is represented by their insistence on using the best ingredients available and then packaging and marketing them in an exclusive format. Together we believe that customers are tired of buying products whose active ingredients simply fail to deliver the desired results. ph2™ provides customers with a therapeutic level of all 8 catechins and then protects these valuable, thermogenic-producing molecules until they reach the blood stream. We're excited to be working together and anticipate great things for their product."

Kevin Coyne, Managing Director of Coyne Healthcare, added, "Plandaí's ability to deliver ph² fits perfectly with our goal of ensuring that our products perform exactly as represented on the label. Most nutraceutical products use inferior ingredients, incorrectly assuming, for instance, that green tea is green tea. This simply isn't the case. Coyne Healthcare requires that a therapeutic level of the active ingredients make it to the blood stream intact and are then absorbed by the targeted cells. ph2™ does just that, making our new product the first of its kind in the world."

Founded in Cape Town, South Africa, Coyne Healthcare has been both developing and distributing high quality nutraceutical and food supplements since 2013. For additional information, visit: www.coynehealthcare.co.za

About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

Contact Information